MedTrace Logo

Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies

NCT05127135 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-11-19

No results posted yet for this study

Summary

This is a single dose escalation study to evaluate the safety and clinical activity of ThisCART7(Allogeneic CAR-T targeting CD7) in patients with refractory or relapsed CD7 positive T cell malignancies.

Conditions

  • T-Acute Lymphoblastic Leukemia
  • T-cell Non-Hodgkin Lymphoma
  • T-cell Acute Lymphoblastic Lymphoma

Interventions

BIOLOGICAL

ThisCART7 cells

0.5-6 x 10\^6 CAR T cells per kg body weight

Sponsors & Collaborators

  • The First Affiliated Hospital of University of Science and Technology of China

    collaborator OTHER

  • Fundamenta Therapeutics, Ltd.

    lead INDUSTRY

Principal Investigators

  • Wang Xingbing · The First Affiliated Hospital of USTC (Anhui Provincial Hospital)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
3 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-22
Primary Completion
2023-01-24
Completion
2023-12-24

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05127135 on ClinicalTrials.gov